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Human Immunodeficiency Virus-1 (HIV-1) is an enveloped retrovirus that preferentially 
infects activated CD4+ T helper lymphocytes. After completion of reverse transcription, HIV-1 
cDNA integrates into the host genome. Latency arises when HIV-1 infects an activated CD4+ T 
cell as the cell is returning back to a resting memory state. Critical host cell transcription factors, 
NFκB and NFAT, are also required for HIV-1 transcription, but are inactive in resting T cells. 
This results in a stably integrated but transcriptionally silent form of the viral genome in a long-
lived memory CD4+ T cell. Activation of a latently infected resting memory CD4+ T cell can 
give rise to replication-competent virus. Longitudinal analyses of latently infected cells purified 
from infected patients suppressed on ART (combination antiretroviral therapy) demonstrated that 
this infected cell population has a long half-life of 44 months and requires life-long ART to 
eliminate all infected cells. Therefore, the stability of the latent reservoir is the major barrier to 
curing HIV-1 infection. While there have been major efforts in the field to discover therapeutic 
strategies to reverse latency in order to reduce or eliminate the reservoir, there is a lack of an 
assay that can accurately quantify the true size of the latent reservoir. Without a reliable measure, 
eradication clinical trials will not be able to determine whether or not there has been a true 
reduction in the frequency of latently infected cells harboring replication-competent virus.  
Here, I describe the advantages and disadvantages of current assays used in the field to 
measure the size of the latent reservoir. In addition, my thesis research involved developing a 
novel in vitro assay that provides a more accurate measure of the size of the latent reservoir of 
replication-competent virus. This work has revealed that latently infected cells, including clonally 
expanded cells, release replication-competent virus in a stochastic manner after multiple rounds 
of maximal T cell activation. My work highlights the need to develop additional assays that 
accurately measure the size of the latent reservoir and suggests the need to address reservoir 
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There are currently 35 million people worldwide infected with Human Immunodeficiency 
Virus Type 1 (HIV-1). Without life-long antiretroviral therapy, most of these individuals will die 
of Acquired Immunodeficiency Syndrome (AIDS). However, to date, only 15 million infected 
people are on combination antiretroviral therapy (http://www.cdc.gov/hiv/statistics/basics/). 
Although combination antiretroviral therapy (ART) is effective in suppressing HIV-1 replication 
by blocking various steps in the viral life cycle, it is not curative due to the existence of a latent 
viral reservoir (LR) in resting memory CD4+ T cells1-5. The LR has an extremely long half-life 
(44 months), necessitating lifelong treatment6,7. The LR is established when HIV-1 infects 
activated CD4+ T cells as they are returning to a resting memory state as part of the normal 
physiological process after encountering cognate antigen8,9. Thus, latent proviruses are found 
predominantly in different subsets of resting memory cells. The virus does not replicate in resting 
CD4+ T cells due to blocks at numerous steps of the viral life cycle1,10-12. Latently infected resting 
memory CD4+ T cells are nonpermissive for viral gene expression, and the viral genome persists 
as integrated proviral DNA that is transcriptionally silent13. For this reason, latently infected cells 
are not targeted by the immune system or ART. The LR in resting memory CD4+ T cells is widely 
recognized as a major barrier to HIV-1 eradication. 
The goal of HIV-1 cure strategies is to significantly reduce or eliminate the LR such that 
patients can successfully come off ART without subsequent viral rebound or have a significant 
delay in rebound once stopping ART. With no interventions to reduce the LR, most patients 
typically rebound within a few weeks after stopping ART. To date, only one person has been 
cured of an established HIV-1 infection. This individual (the “Berlin Patient”) was HIV-1-
infected and on ART when he developed acute myeloid leukemia. After an extensive 
conditioning chemotherapy regimen, he received a hematopoietic stem cell transplant (HSCT) 
from an HLA-matched donor whose cells were homozygous for a deletion in CCR5, a co-
receptor used for HIV-1 entry into target cells14. This patient received a new immune system that 
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was resistant to HIV-1 infection and has had no viral rebound since stopping ART after his 
transplant nearly 8 years ago. Although a HSCT resulted in the only documented cure thus far, 
this procedure is not feasible for HIV-infected patients who do not have cancer. Due to the 
stability of the LR, the field has instead turned to identifying pharmacological agents that can 
force the virus out of latency and eliminate the LR, defined as the ‘shock and kill’ strategy15.  
In conjunction with identifying therapeutic strategies to eliminate the LR, there is a need 
to have an assay that accurately measures the size of the LR. Current PCR- and culture-based 
assays overestimate and underestimate the size, respectively, and don’t correlate well with one 
another16,17. As cure trials move forward, there is a critical need to develop an assay that 
accurately measures the effectiveness of an eradication strategy17.  
For my thesis work, I hypothesized that repeated maximum stimulation of latently 
infected, resting CD4+ T cells would induce additional outgrowth of replication-competent virus 
and provide a more accurate measurement of the LR. To address this hypothesis, I designed a 
novel in vitro assay that involved isolating and culturing resting CD4+ T cells isolated from 
peripheral blood from 12 patients on suppressive ART. Resting CD4+ T cells were subjected to 
four subsequent rounds of maximal T cell activation at weekly intervals. In addition, I analyzed 
outgrowth viruses to determine whether certain inducible provirus would require only one round 
of activation vs multiple rounds for outgrowth. I sequenced two short regions within the viral 
genome in both the LTR and env genes and found that, in 9 out of 12 patients, different rounds of 
stimulation caused outgrowth of identical viral isolates by sequence. This result is consistent with 
previous work showing in vivo clonal expansion of infected cells carrying replication-competent 
virus18-21. Taken together, my work strongly supports the novel concept of stochastic reactivation 
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 The latent reservoir of HIV-1 in resting memory CD4+ T cells serves as a major barrier 
to curing HIV-1 infection. While many PCR- and culture-based assays have been used to measure 
the size of the latent reservoir, correlation between results of different assays is poor and recent 
studies indicate that no available assay provides an accurate measurement of reservoir size. The 
discrepancies between assays are a hurdle to clinical trials that aim to measure the efficacy of 
HIV-1 eradication strategies. Here we describe the advantages and disadvantages of various 




Measurement and composition of the latent reservoir  
The latent reservoir (LR) was first measured and characterized in the mid-1990s using a 
viral outgrowth assay (VOA), which is still considered the gold standard for measuring the 
frequency of resting CD4+ T cells that carry replication-competent proviruses in a latent state3,22. 
The VOA makes use of phytohemagglutinin (PHA), a strong T cell mitogen, to globally activate 
resting CD4+ T cells in a manner that mimics antigen-driven activation. This renders the cells 
permissive for viral gene expression and induces release of HIV-1 from latently infected cells. 
Since the development of the VOA, other assays such as PCR-based ones that measure total HIV-
1 proviral DNA, have been advanced as simpler measures of the LR23-25. Although both culture- 
and PCR-based methods are commonly used, there is little correlation between the two types of 
assays. Based on the VOA, approximately 1 per 106 resting CD4+ T cells contain replication-
competent virus, but PCR-based assays show that on average 300 per 106 resting CD4+ T cells 
contain HIV-1 proviral DNA16.  
These discrepancies are attributed to the heterogeneous nature of the proviruses in resting 
CD4+ T cells. These proviruses can be divided into two groups: those that are induced to release 
replication-competent virus after one round of T cell activation (induced proviruses) and those 
that are not (non-induced proviruses), as is shown in Figure 2.1. The VOA measures only the 
former population, whereas PCR-based approaches detect both groups of proviruses. This 
partially explains the lack of correlation between the two types of assays. Interestingly, most 
noninduced proviruses are defective26. The majority contain large internal deletions that arise by 
copy choice recombination between homologous regions in genomic viral RNA during reverse 
transcription26-28. Other defective proviruses contain inactivating G to A nucleotide substitutions 
introduced by APOBEC3G, a cytidine deaminase that is part of the host innate immune defense 
system29-31. A small percentage of proviruses contain other inactivating defects such as packaging 
signal deletions, small nucleotide insertions or deletions (INDELS), and missense mutations. 
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Defective proviruses will not produce infectious virus in the VOA but can be detected by PCR 
assays, depending on the assay specifics. In addition, a small percentage of noninduced 
proviruses have intact genomes and are potentially replication-competent26. These proviruses are 
termed intact, noninduced proviruses (INPs). In order to achieve a sterilizing HIV-1 cure, all of 
the proviruses capable of reinitiating infection must be purged from the LR.  
Accurately measuring changes in the size of latent reservoir 
Currently, the most widely discussed approach to eliminate the LR is to reverse latency 
pharmacologically so that the infected cells can be eliminated. This approach is termed ‘shock 
and kill’15,32,33. The rationale is to first force HIV-1 out of latency by inducing expression of HIV-
1 genes since high levels of certain HIV-1 proteins can cause death of the infected T cells through 
cytopathic effects. In addition, presentation of peptides derived from viral proteins can lead to 
lysis of infected cells by virus-specific cytolytic T lymphocytes (CTL). Cell surface expression of 
the HIV-1 envelope glycoprotein (Env) can, in principle, target infected cells for destruction by 
antibody-dependent cell-mediated cytotoxicity (ADCC). In addition, downregulation of MHC 
class I molecules by the HIV-1 accessory factor Nef can render productively infected cells 
susceptible to lysis by natural killer (NK) cells34. 
Clinical trials involving the ‘shock and kill’ strategy are in progress. Histone deacetylase 
inhibitors (HDACis) reverse HIV-1 latency in model systems and are being tested in infected 
individuals on ART35-41. However, recent studies have shown a discrepancy between the effects 
of latency reversing agents (LRAs) in in vitro HIV-1 latency models and in ex vivo assays with 
cells from HIV-1 infected individuals42-44. In order to determine if these LRAs are effective, it is 
important to develop techniques that accurately measure changes in the LR size in vivo.   
Significant progress has been made in developing culture- and PCR-based assays since 
the initial discovery of the LR in the 1990s. However, a detailed comparison of several current 
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assays has shown no precise correlation16. Available assays are discussed below, and their 
advantages and disadvantages are summarized in Table 2.1.  A high-throughput, reliable, and 
sensitive assay that can accurately measure the true size of the LR is urgently needed. Such an 
assay is essential for determining the efficacy of pharmacological agents used in current or future 
clinical trials and for reliably concluding that a sterilizing cure has been achieved in HIV-1-
infected patients undergoing eradication treatments. 
Culture-based assays to measure the latent reservoir  
The LR was initially defined and measured using the VOA3. This assay is still considered 
the ‘gold standard’ for measuring the LR. In this assay, resting CD4+ T cells are isolated from 
patients on ART and plated in fivefold serial dilutions. Phytohemagglutinin (PHA), a lectin, is 
added along with irradiated allogeneic peripheral blood mononuclear cells (PBMCs) to induce 
global T cell activation. The PBMCs ensure successful activation since they contain macrophages 
and dendritic cells, which act as antigen-presenting cells and enhance the PHA-driven activation 
of T lymphocytes22. These conditions give uniform activation of resting CD4+ T cells as assessed 
by CFSE dilution45. Initially, CD4+ lymphoblasts from HIV-1-negative donors were used to 
expand virus released from the patient cells to detectable levels. This process can be simplified by 
using the continuously proliferating cell line, MOLT-4/CCR5, which expresses high levels of 
CD4 and CXCR4 and has been stably transfected with CCR5, a co-receptor for HIV-1 viral 
entry46. The patient cells are co-cultured with lymphoblasts or MOLT-4/CCR5 cells for two to 
three weeks and then culture supernatants are analyzed for free virus using an ELISA assay for 
HIV-1 p24 antigen. Alternatively, a highly sensitive RT-PCR assay for virus in the supernatant 
can detect viral outgrowth as early as seven days after activation46. 
The VOA has a number of advantages, including the ability to detect individual latently 
infected cells. The clonal viruses that grow out in wells seeded at limiting dilution can be 
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characterized by sequencing and functional studies. The VOA has the additional advantage of not 
detecting defective proviruses, which vastly outnumber replication-competent proviruses and 
which are detected in standard DNA PCR assays26. However, some recent studies have shown 
that the VOA underestimates the true size of the LR because viral outgrowth is not observed in all 
wells that contain cells with intact proviruses. When wells negative for viral outgrowth were 
stimulated a second time with PHA, outgrowth of replication-competent virus was observed26. 
There are several potential explanations for the initial failure of these INPs to give rise to viral 
outgrowth following cellular activation. Viral induction could represent a stochastic process such 
that each intact provirus has only a finite probability of becoming induced following cellular 
activation. Most HIV-1 proviruses integrate into introns of actively expressed cellular genes47, 
and transcriptional interference from the host gene could reduce the probability that a given intact 
provirus will be induced by a single round of T cell activation. However, the same provirus may 
be induced by subsequent rounds of T cell activation. Additionally, some of these INPs could 
have been successfully induced to produce viral RNA and release infectious virions. However, 
the released virus may have failed to establish a spreading infection that is required for detection 
by the VOA. For these reasons, the LR may actually be larger than the average value of one 
replication-competent provirus per 106 resting CD4+ T cells, as measured by the VOA26. Thus, 
the VOA is best regarded as a definitive minimal estimate of the frequency of latently infected 
cells. 
In addition to underestimating the size of the LR, the VOA can be problematic because it 
uses large volumes of blood (120-180 mL), is labor intensive and expensive, and requires 1-3 





T cell activation assays with viral RNA readout 
Other culture-based assays used to measure the LR include ones in which patient resting 
CD4+ T cells are plated and maximally activated at limiting dilution such that there is less than 
one virus-producing cell per well. Following maximal T cell activation, the frequency of cells 
producing viral RNA is directly measured by a quantitative PCR (qPCR) specific for either cell-
associated unspliced mRNA43, multiply spliced mRNA45, or HIV-1 mRNA in the culture 
supernatant (presumably reflecting virion release)43,46. These assays measure different forms of 
RNA present throughout the HIV-1 life cycle. It is important to identify what form of HIV-1 
RNA is being detected since these represent different stages in replication. Early in the replication 
cycle, multiply spliced mRNA transcripts are generated, but with time the transcripts are 
increasingly exported as unspliced and singly spliced mRNA species. Some mRNA transcripts 
are translated to make viral proteins necessary for virion assembly while other full-length 
transcripts are packaged into newly assembled virions for subsequent infection. When virions are 
released from the infected cell, certain assays can measure the two full-length mRNA copies that 
are present within a single virion. A recent study compared virion release with intracellular RNA 
measurements and found that, on average, 1.5% of proviruses could be reactivated to produce 
HIV-1 virions, whereas 6.8% and 8.2% of proviruses from two different patients could be 
reactivated to produce unspliced cell-associated HIV-1 RNA43. Since HIV-1 mRNA present in 
the culture supernatant reflects virus production, this measurement is likely a more accurate 
quantification of the LR. In summary, these RNA-based assays allow for detection of infected 
cells with no need for outgrowth of the virus before PCR measurement, shortening the length of 
required culture time. However, the same caveats that apply to the VOA also apply to these 
assays. Since they only involve a single round of T cell activation, they do not detect INPs within 
the LR. Additionally, some defective proviruses may be able to produce RNA and even release 
virions even though they are unable to produce infectious virions. These defective proviruses 
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could be detected by these assays. Thus, this class of assays may be confounded by both false 
negative and false positive results and do not accurately measure the size of the LR.   
PCR-based assays to measure the latent reservoir 
PCR-based assays are commonly used to measure persistent HIV-1 and provide a 
complementary approach to the VOA. These methods provide a quicker and easier way to study 
viral persistence and can be applied to a variety of immune cell types. The most common PCR 
method for measuring the LR is a qPCR for proviral DNA in either unfractionated PBMCs23,48-52, 
CD4+ T cells53,54, or resting CD4+ T cells55. All methods involve isolating the desired cell 
populations from the peripheral blood of infected individuals and subsequently extracting the 
DNA. A qPCR using primers located in conserved regions of the HIV-1 genome is carried out on 
the DNA extracts. The number of infected cells is calculated using a standard curve constructed 
with known copy numbers of proviral DNA, typically from a plasmid standard such as pNL4-3. 
A qPCR assay for a cellular gene present in two copies per diploid genome (frequently the 
ribonuclease RNase P), is used to determine the total number of cells in the sample. The proviral 
DNA copy number, combined with the total number of cells present, can give an estimate of the 
frequency of cells that harbor HIV-1 DNA. These methods have also been adapted to measure 
proviral DNA in the gut-associated lymphoid tissue (GALT)56-58, a site which contains a high 
frequency of infected cells, as well as in CD4+ T cells in the bone marrow59. Other PCR methods 
use the droplet digital PCR technique to measure HIV-1 DNA in CD4+ T cells16,25 as well as in 
PBMCs16,60,61. This method permits absolute quantification of HIV-1 DNA rather than relative 
quantification derived from a standard curve, as with qPCR.  
In measuring the LR, it is important to detect only stably integrated proviruses and not 
extra-chromosomal HIV-1 DNA forms, which are unstable or replication-defective. Pioneering 
studies by Stevenson and colleagues showed that most of the HIV-1 DNA in resting CD4+ T cells 
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from viremic patients is in a linear, unintegrated form which represents the end product of reverse 
transcription prior to integration62. Following cellular activation, this unintegrated viral DNA is 
integrated and transcribed, ultimately giving rise to infectious virus. Since the VOA involves 
cellular activation, it also detects cells with linear, unintegrated HIV-1 DNA if carried out on 
samples from viremic patients. Several studies suggest that in the absence of integration, the 
linear, unintegrated form of the viral genome is labile63,64. Therefore, cells with unintegrated HIV-
1 DNA should not be considered as part of the stable LR. Following initiation of ART, labile, 
unintegrated viral genomes in recently infected cells decay, and after six months, the frequency of 
cells detected in the VOA falls to a stable plateau65. Importantly, because it can detect cells with 
linear unintegrated viral genomes, the VOA does not give a reliable estimate of the LR in 
untreated patients or in patients who have been on therapy for less than six months. 
Due to the problem of linear, unintegrated HIV-1 DNA, there has been considerable 
interest in PCR assays that can distinguish integrated viral genomes from unintegrated genomes. 
The most common method used for this purpose is Alu-PCR, which has been applied to either 
purified CD4+ T cells or PBMCs24,66-69. Alu-PCR selectively amplifies integrated HIV-1 genomes 
by using one primer targeting Alu elements, which are found in high copy numbers in the human 
genome, and a second primer located in the HIV-1 gag gene. A nested real-time PCR is then 
performed using a second set of primers in the HIV-1 LTR. Controls in which the Alu primer is 
excluded are important to demonstrate that the observed signal is in fact coming from integrated 
HIV-1 DNA. Proviruses integrated in close proximity to Alu elements give shorter first round 
PCR products and will amplify to a greater extent. A standard curve with a mixture of DNA from 
cells with different HIV-1 integration sites is used to account for differential amplification of 
proviruses integrated at different distances from an Alu element, and a correction factor is used to 
account for proviruses that are too far from an Alu sequence to be detected. When compared to 
droplet digital PCR for HIV-1 DNA in patients on suppressive ART, there was a strong 
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correlation, indicating that the majority of HIV-1 DNA in ART patients is integrated16. This 
conclusion is further supported by additional studies showing that unintegrated forms of HIV-1 
DNA are typically found in low levels in patients on suppressive ART48,51,68. Alternative methods 
for measuring integrated proviruses have also been developed and include linker ligation PCR70 
and inverse PCR 1. 
Recently, two different research groups18,19 have improved methods to study the specific 
integration sites of proviruses. Their findings show that a substantial fraction of proviruses (40% 
in one study)18 are integrated into the genomes of cells that have undergone clonal expansion after 
infection. In one patient, approximately half of the infected cells contained a single viral clone 
with the same integration site18. In addition, integration sites were shown to be favored in genes 
that are associated with cancer18,19. These studies suggest that clonal expansion may occur as a 
result of integration into growth promoting genes18, which will cause an expansion in the number 
of CD4+ T cells carrying HIV-1 proviruses. However, it remains unknown whether or not the 
proviruses present in these expanded clones are replication-competent. PCR-based assays will 
detect clonally expanded proviruses regardless of whether or not they are replication-competent, 
while culture-based assays will only detect outgrowth of replication-competent virus. 
Total HIV-1 DNA PCR measurements can also detect other forms of unintegrated 
proviruses that are not a part of the LR. Two-long terminal repeat circles (2-LTR circles) result 
when integration fails and non-homologous end-joining (NHEJ) occurs between the two LTRs of 
linear, unintegrated HIV-1 DNA71. 1-LTR circles also are present during the course of HIV-1 
infection and arise when homologous recombination occurs between linear HIV-1 DNAs at the 
LTRs72. This results in a circularized form of HIV-1 containing only a single LTR. Neither of 
these forms can integrate nor produce infectious virus. Although these forms are not considered 
to be part of the LR, 2-LTR circles have been used as a measure of recent infection or ongoing 
replication, based on the assumption that 2-LTR circles are labile. However, the stability of 2-
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LTR circles remains controversial49,73-75. Several assays have been developed to study 2-LTR 
circles, including a droplet digital PCR assay on resting CD4+ T cells and PBMCs16,61, as well as 
a qPCR assay on PBMCs49,76 and CD4+ T cells73. These assays use primers flanking the 2-LTR 
circle junction. 1-LTR circles are more difficult to quantify using PCR1,77,78. It remains unclear 
how measurements of these replication-defective circular forms will contribute to our 
understanding of HIV-1 reservoirs. 
It is important to understand the relationship between PCR-based assays for proviral 
DNA and other assays of the LR. As discussed above, PCR assays for HIV-1 proviruses give 
infected cell frequencies that are at least two logs higher than those obtained by the VOA16. This 
is due to the fact that PCR methods detect many defective proviruses as well as replication-
competent proviruses. A recent study by Ho and colleagues26 characterized INPs and found that 
almost 90% of these proviruses are defective and contain large internal deletions, APOBEC3G-
induced hypermutations, or other inactivating mutations (Figure 2.1). Detection of these 
defective proviruses helps explain the overestimation of the LR size by PCR-based assays.  
An additional concern with PCR-based assays is that they may fail to detect changes in 
LR size since most of the PCR signal is from defective proviruses that may respond differently to 
LRAs. Many defective proviruses may be unable to produce viral proteins even if latency is 
successfully reversed. Elimination of infected cells is likely dependent upon viral protein 
production, and thus cells containing defective proviruses may not be eliminated even by 
successful strategies. Thus, large numbers of cells with defective viruses could potentially mask 
successful clearance of latently infected cells by eradication strategies. In summary, the VOA 
underestimates the true size of the LR since one round of activation does not induce outgrowth of 
all replication-competent proviruses. On the other hand, PCR assays for HIV-1 DNA dramatically 
overestimate the LR since they cannot discriminate between defective and replication-competent 
proviruses.   
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Measuring residual viremia 
While ART is effective in suppressing viremia to below the clinical limit of detection (50 
copies of HIV-1 RNA/mL of plasma), HIV-1 RNA can still be detected at low levels in the 
plasma, indicating persistent residual viremia79. To measure residual viremia, Palmer and 
colleagues developed a highly sensitive single-copy assay (SCA). This assay can detect HIV-1 
RNA down to one copy per mL of plasma80-82. The SCA is an RT-PCR assay that uses primers 
located in a conserved region of gag in the HIV-1 genome. It measures ongoing viral production 
from CD4+ T cells or from other stable reservoirs83.  Another version of the SCA that uses a 
larger volume of plasma and primers located in a conserved region of integrase has recently been 
described84. 
Sequence analysis of residual viremia show that it is archival in character and sensitive to 
the current ART drugs85,86. These results suggested that residual viremia results from release of 
virus from stable reservoirs rather than ongoing viral replication. This hypothesis was 
substantiated in 2009 by the addition of a fourth drug to the three drug ART regimens of patients 
who had stable suppression of viremia to below 50 copies/mL This addition did not further 
reduce residual viremia87 and further treatment intensification studies have confirmed this 
result51,88-91. Thus, residual viremia reflects virus production by a stable reservoir of cells infected 
prior to the initiation of therapy. In this sense, it can be used as a measure of viral reservoirs. 
However, the nature of the cells that produce the residual viremia is not yet clear. It is certainly 
possible that residual viremia results from the activation of a small fraction of the resting CD4+ T 
cells that constitute the LR. However, residual viremia in patients on ART is frequently 
oligoclonal83,92. Despite the enormous sequence diversification that occurs during HIV-1 
infection, the residual viremia in many patients is dominated by a single clone, termed a 
predominant plasma clone (PPC). Proviruses with the same sequence can be found in resting 
CD4+ T cells in the blood, but there is not a 1:1 correspondence between plasma and cellular 
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sequences83,93. This may reflect the large fraction of defective proviruses26 or possibly the 
presence of an additional reservoir. The relationship between the PPC and the expanded clones of 
infected cells described above remains unclear. Thus, the relationship between residual viremia 
and the LR is complex. While the SCA is a useful tool for measuring viral persistence in the 
plasma, it may not accurately quantify changes in the LR in patients in eradication trials.    
Treatment interruption and time to rebound as a measurement of latent reservoir size  
Initially, following the introduction of ART, it was thought that only a few years of 
treatment would be sufficient to cure HIV-1 infection94. However, the discovery of the LR and its 
long-term stability indicates that patients must remain on ART for their entire lives to prevent a 
rebound in viremia6,7, which typically occurs within a few weeks of stopping treatment95. As viral 
rebound reflects release of virus from stable reservoirs, there is a growing trend to evaluate 
reservoir reductions in HIV-1 eradication studies by stopping ART and observing the time it takes 
for viral rebound to occur14,60,96,97. This was done in the case of the two HIV-1 positive patients 
who received allogeneic stem cell transplants from CCR5-wild type donors while on ART. The 
transplants were done to treat Hodgkin’s lymphoma in one case and diffuse large B-cell 
lymphoma and subsequent Hodgkin’s lymphoma in the other case97. Although the patients 
(known as the ‘Boston patients’) had undetectable levels of HIV-1 DNA, both experienced a 
rebound of viremia several months after stopping ART98. In another example, a baby born to an 
HIV-positive mother (the ‘Mississippi baby’), was given ART 30 hours after birth and, 
subsequently, viremia fell to undetectable levels and remained below the limit of detection. ART 
was discontinued against medical advice 18 months after initiation of treatment99. The baby 
showed no signs of virus in her blood following treatment cessation for over two years, but had a 
sudden rebound in viremia after 27 months off ART100. Interestingly, in all three cases, HIV-1-
specific immune responses were absent. The long-term persistence of replication-competent HIV-
1 in the absence of HIV-1-specific immune responses provides dramatic proof that the virus can 
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persist in vivo in a latent form. These examples demonstrate that with a very small LR resulting 
from transplantation or early treatment, there is a substantial delay in the time to rebound.  
Although treatment interruption is ultimately the only way to determine if a patient is 
cured, there are precautions and ethical issues to consider when using ‘time to rebound’ as a 
measurement of LR size. Drug resistance can occur if the interruption or subsequent reinitiation 
of ART is done in a way that allows suboptimal drug concentrations to be present for a significant 
period of time101,102. One of the Boston patients developed a new resistance mutation while 
restarting therapy98. The Strategies for Management of Antiretroviral Therapy (SMART) study, 
conducted in 2006, compared the effects of episodic treatment interruption to continuous ART 
and found that the patients who underwent treatment interruption experienced higher levels of 
morbidity, opportunistic diseases, and malignancies compared to those on continuous ART103-106. 
Additional difficulties with this approach include the enormous variability in time to rebound. If 
the LR is reduced significantly in size but not entirely eliminated, rebound could be governed by 
stochastic processes and may occur unpredictably months or years after treatment interruption107. 
Thus, treatment interruption is problematic in evaluating reservoir reductions.  
Current measurements in eradication clinical trials  
As LRAs are meant to induce transcription of the latent provirus, methods to detect 
changes in HIV-1 RNA levels are used to evaluate their efficacy in eradication studies. Methods 
using qPCR have been developed for measuring steady state HIV-1 RNA levels in PBMCs50,57, 
resting CD4+ T cells35, and in the GALT16,57. Droplet digital PCR has also been used to quantify 
HIV-1 RNA 108, and a recently described method detects polyadenylated HIV-1 mRNAs in 
resting CD4+ T cells42. Most studies also incorporate careful measurements of HIV-1 RNA in the 
plasma to detect transient increases in viral production. Recently, small increases in HIV-1 RNA 
in the detectable range have been documented in patients receiving the HDACi panobinostat41. In 
18	  
	  
addition to determining whether or not a LRA has been effective in ‘shocking’ latently infected 
cells to produce viral RNA, it is also important to determine whether or not the infected cells have 
been ‘killed’ and eliminated from the reservoir109. In order to do this, an accurate measure of the 
LR before and after treatment(s) is necessary. Currently, the VOA provides the most definitive 
way to do this. To date, no significant reduction in the LR has been achieved by any ‘shock and 
kill’ strategy. Current and future eradication trials involve HDACis38,40,41, gene therapies60, and 
treatment intensifications110. Most current and future trials will measure LRA efficacy by 
decreases in the frequency of latently infected cells as measured by the VOA, increases in 
transient LRA-induced cell-associated HIV-1 RNA, or the appearance of plasma HIV-1 RNA. 
Some studies also measure total and integrated HIV-1 DNA or utilize a combination of multiple 
measures (Table 2.2). In interpreting the outcomes of these trials, it will be important to keep in 














Following the discovery of the LR in resting memory CD4+ T cells and its long-term 
stability, identifying ways to eliminate the LR has become a research priority. It is equally 
important to develop better ways to measure the LR111, since current and future eradication trials 
lack a universal measure to assess whether or not a decrease in the LR has been achieved. 
Although many assays have been developed to quantify the LR, there is little correlation between 
the methods16 and none measure the true LR size as is shown in Figure 2.2. Additionally, there 
are also disadvantages to both PCR- and culture-based assays that need to be considered when 
measuring the LR or evaluating eradication therapies. The VOA is still considered the gold 
standard for measuring the LR since it provides a definitive minimal estimate of reservoir size. 
However it does not detect all latently infected cells that contain replication-competent virus26. 
Underestimating the size of the LR may give the false impression that a patient is ‘cured’ when 
the patient may still have latently infected cells. If taken off ART, a patient may experience a 
rebound in viremia, as was the case with the Boston patients98 and the Mississippi baby100. PCR-
based assays are also commonly used to quantify proviral DNA, but they cannot distinguish 
between replication-competent and defective proviruses. A failure to distinguish between the two 
would make it impossible to know when the LR has been successfully cleared and when or if 
patients can safely interrupt therapy. Treatment interruption is also used to measure a reduction in 
reservoir size; however, there are many concerns with this approach including increased risks for 
drug resistance and disease progression. Thus, there remains a need for assays that can measure 
the effects of therapeutic interventions on reservoir size without the need for treatment 
interruption. When applied to the ‘shock and kill’ strategy, neither culture- or PCR-based assays 
can adequately measure both the ‘shock’ and the ‘kill’ aspects. However, it may not be necessary 
to use the same assay to measure both the ‘shock’ and the ‘kill’. Certain assays may be better 
suited to measure each aspect. For instance, RNA-based culture assays may provide a rapid 
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measure for the ‘shock’, but assays such as the VOA may be best suited for measuring the ‘kill’.  
In the absence of a universal assay, clinical trials are using a combination of culture- and PCR-
based methods to identify and measure changes in the LR (Table 2.2). However, the conclusions 
drawn from these trials will vary depending on the measurements used. Without a high 
throughput, sensitive, and well-validated assay, it will remain difficult for researchers to identify 








Figure 2.1. Profile of different types of HIV-1 proviruses in resting CD4+ T cells.  
The major types of proviruses are shown, including those that pose a barrier to an HIV-1 cure and 
those that do not. Following a single round of T cell activation, some proviruses are induced to 
produce virions, which can infect other cells (induced, replication-competent proviruses). 
Proviruses that are not induced to produce replication-competent virions following a single round 
of T cell activation are termed noninduced proviruses26. Many of these noninduced proviruses are 
defective and contain large internal deletions, G→A hypermutations, or other inactivating 
defects. However, some noninduced proviruses have fully intact genomes and, on subsequent 
rounds of cellular activation, can produce virions. These proviruses are termed intact, noninduced 
proviruses (INPs). Culture-based assays detect induced replication-competent proviruses only, 
while PCR-based assays detect all types of proviruses. Only induced replication-competent 




Figure 2.2. Venn diagram comparison of proviral populations measured by different 
methods of assessing the latent reservoir (LR). 
 Typical or estimated results from various PCR- and culture-based assays are shown relative to a 
prediction of the true LR size. The frequency of infected cells detected by the different assays is 
represented by the area of each circle. PCR-based assays overestimate the LR since most of the 
templates amplified represent defective viruses26. Additionally, some proviruses are likely to be 
deleted in the primer binding sites for the PCR, so PCR-based assays are likely to underestimate 
the total number of infected cells. The viral outgrowth assay (VOA) underestimates the LR size 
because not every replication-competent virus is induced by a single round of T cell activation26. 
Assays involving T cell activation with a viral RNA readout give intermediate values but suffer 
from both of the problems mentioned above: some of the viral RNA detected is derived from 
defective proviruses and not all of the replication-competent proviruses are induced by a single 
round of activation. There is a need for assays that measure only those proviruses that pose a 










Table 1. Comparison of Assays for Measuring the HIV-1 Latent Reservoir!



















p24 ELISA or 
RT-PCR 






Expensive, requires a large 
sample volume (120-
180mL), and is time 
consuming requiring 2-3 
weeks in a BSL3 
laboratory. 
 
Does not detect all 
proviruses that potentially 








Fraction of proviruses 
that can be induced to 
make either cell 
associated unspliced or 
multiply spliced HIV-1 
RNA or full length HIV-1 






induced to make 
HIV-1 RNA after a 
single round of 
activation 
RT-qPCR  No need for 
amplification of virus 
before measurement. 
 
Less culture time is 
required than the VOA. 
 
Requires 2-7 days of 
culture in a BSL3 
laboratory. 
 
Does not detect all 
proviruses that potentially 
pose a barrier to a cure. 
 




HIV-1 DNA  







qPCR Easy, quick, and does 
not require any 
extended culture time in 
a BSL3 laboratory. 
Detects many proviruses 
that do not pose a barrier 
to an HIV-1 cure. 
 
Provides a quantitation 
relative to a standard 
curve, but not an absolute 
value. Different qPCR 







Integrated proviral DNA Unintegrated 
proviral DNA 
including 2-LTR 
circles and linear 
unintegrated HIV-
1 DNA 
qPCR Is useful in measuring 
integrated proviruses in 
untreated patients, when 
large numbers of 
unintegrated DNA can 
confound total proviral 
DNA measurements. 
Does not detect integrated 
proviruses that are too far 
from an Alu sequence to 
be detected, but uses a 
standard curve to correct 
for these. 
 















ddPCR Highly precise. Provides 
an absolute quantitation 
rather than a relative 
one. 
Detects many proviruses 
that do not pose a barrier 







Total proviral DNA in the 
GALT including 
replication-competent, 
defective provirus, and 
unintegrated DNA 
Proviruses 
located in sites 
other than the 
GALT 
qPCR Allows for the 
measurement of viral 
persistence in the GALT 
of patients. 
Assay input requires cells 







2-LTR circles Integrated proviral 
DNA 
qPCR Is useful in measuring 
ongoing replication in an 
untreated patient. Has 
been used as a measure 
of time since infection.  
Doesn’t detect integrated 
provirus, which is the only 









2-LTR circles Integrated proviral 
DNA 
ddPCR Highly precise. Provides 
an absolute quantitation 




replication in an 
untreated patient. 
Doesn’t detect integrated 
provirus, which is the only 









Total proviral DNA in 
CD4+ T cells located in 
the bone marrow 
including replication-
competent and defective 
provirus 
Proviruses 
located in sites 
other than the 
bone marrow 
qPCR Allows for the 
measurement of viral 
DNA in sites other than 
CD4+ T cells in the 
peripheral blood. 
Assay input requires a 
large sample volume of 
bone marrow aspirate 





Residual viremia in 
plasma 
Proviral DNA 
within cells or 
compartments 
RT-PCR Highly precise and 
requires a very small 
sample volume (8mL of 
plasma). 
Time consuming and 
doesn’t provide information 
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Plasma RNA by SCA, total 
DNA, 2LTR circle DNA, 
cell-associated RNA, 





UCSF ACE inhibitor Change in RNA in total 
CD4s and in GALT, and 















VOA, total and integrated 
DNA in CD4s, cell-
associated unspliced RNA 
in CD4s, and plasma RNA 
December 2015 





cells with or 
without IL-2 
Plasma RNA by SCA, 
tissue RNA, frequency of 
latent replication-
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e inhibitor  
Cell-associated RNA in 
total and resting CD4s, 
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TLR-3 agonist  Cell-associated RNA, 









Cell-associated RNA in 
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and 2-LTR DNA circles in 







Institute for Health and 
Medical Research-
French National 
Agency for Research 






Plasma RNA by SCA 
during and after stopping 





University of North 
Carolina at Chapel 
Hill/Argos 
Therapeutics/U.S. 




and HIV strain 
Plasma RNA by SCA and 
VOA 
January 2016 
New Era Study NCT00908544 
 





DNA in PBMCs and total 









Cytokine Alu-HIV gag PCR to detect 












DNA in sorted CD4 
subsets, plasma RNA by 
SCA, HIV-1 DNA in 
PBMCs and total CD4s, 
defective DNA sequences 










Repetitive stimulation reveals stochastic reactivation of latent 
HIV-1 from infected CD4+ T cells including expanded cellular 









Human Immunodeficiency Virus-1 (HIV-1) establishes latency in resting memory CD4+ 
T cells. These latently infected cells serve as a major barrier to eradication. The standard measure 
of the size of this latent reservoir is the viral outgrowth assay (VOA), in which maximum 
activation of resting CD4+ T cells is used to reverse latency and induce viral outgrowth in 
samples from patients on suppressive antiretroviral therapy (ART). Previous studies have shown 
that the VOA underestimates the size of the latent reservoir because some cells carrying intact 
proviruses do not release replication-competent virus after a single round of maximal T cell 
activation. We show here in studies of 12 patients on suppressive ART that additional viral 
outgrowth can be observed after each of three additional sequential rounds of T cell activation. 
Repetitive stimulation yielded large numbers of independent isolates of replication-competent 
virus from individual patients, thereby providing a better indication of the true size of the latent 
reservoir. Sequencing revealed that many isolates from a given patient were identical, consistent 
with dramatic in vivo clonal expansion of infected cells carrying replication-competent virus. 
Identical replication-competent viruses were often obtained from different rounds of maximal T 
cell activation, strongly supporting the concept of stochastic reactivation of intact proviruses from 




More than 35 million people in the world are living with Human Immunodeficiency 
Virus-1 (HIV-1) infection, and approximately 47,352 new infections occur every year in the 
United States alone (http://www.cdc.gov/hiv/statistics/basics/). The development of combination 
antiretroviral therapy (ART) in the mid 1990’s significantly reduced mortality for those infected. 
However, ART alone is not curative due to the ability of HIV-1 to persist in a latent form within 
immune cells, specifically resting memory CD4+ T cells1-5. HIV-1 replicates preferentially in 
activated CD4+ T cells112,113. Resting CD4+ T cells are less permissive for HIV-1 replication due 
to low expression of the CCR5 coreceptor114, low dNTP levels maintained by the restriction 
factor SAMHD1115, a rigid actin cytoskeleton116, and lack of functional forms of key activation-
dependent transcriptional activators including NFκB, NFAT, and pTEFB117-121. HIV-1 may 
establish latent infection when activated CD4+ T cell are infected as it as they reverting back to a 
resting memory state that is non-permissive for viral gene expression4,8,122.  Direct infection of 
resting cells may also occur, especially with viruses that can utilize the CXCR4 coreceptor for 
entry123,124. In resting memory CD4+ T cells, the integrated viral genome (provirus) is not 
transcribed, making it difficult to detect or quantify latently infected cells125. Because of its 
stability6,7, the latent reservoir (LR) in resting memory CD4+ T cells is the major barrier to 
eradication of HIV-1.  
The standard assay used to measure the size of the LR is the viral outgrowth assay (VOA) 
3,6,22. This assay requires the isolation and limiting dilution culture of resting memory CD4+ T 
cells from patients on suppressive ART in the presence of PHA (phytohemagglutinin) and 
irradiated healthy donor peripheral mononuclear blood cells (PBMCs). This causes maximum 
activation of the patient CD4+ T cells45,126, which reverses latency and allows release of 
infectious virus. Healthy donor CD4+ T lymphoblasts or a transformed CD4+ T cell line (MOLT-
4) 46 are added to the culture to amplify virus that is released from infected patient cells following 
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reversal of latency. The standard VOA is carried out for 2 weeks, and the readout for viral 
outgrowth is a p24 ELISA assay that detects the capsid protein present in the virion. RT-PCR can 
also be used to detect exponentially increasing levels of virus in the supernatant46. Viral 
outgrowth is quantified in terms of infectious units per million (IUPM) resting CD4+ T cells. The 
resulting IUPM value represents the frequency of latently infected cells containing readily 
inducible, replication-competent virus. 
In multiple laboratories, the frequency of latently infected cells measured by the VOA 
falls in a two log range, 0.1-10 IUPM6,7. These measurements are based on the number of wells in 
which viral outgrowth is observed after one round of maximum T cell activation with PHA. 
Interestingly, the frequency of cells with HIV-1 DNA, as measured by PCR-based methods, is 
approximately 300-fold higher than the frequency of latently infected cells measured by the 
VOA16. Ho et al. demonstrated that this discrepancy is due to the presence of large numbers of 
proviruses that are not induced to produce replication-competent virus in the VOA26. The 
majority of these noninduced proviruses have lethal mutations, such as large internal deletions or 
APOBEC3G-induced hypermutation26. However, full-length sequencing of non-induced 
proviruses revealed that a small fraction of these (12%) are genetically intact with no obvious 
defects. When reconstructed by gene synthesis, these intact, non-induced proviruses replicate well 
in vitro. To determine whether any of these intact, non-induced proviruses could be induced, cells 
in wells negative for viral outgrowth were subjected to a second round of maximum T cell 
activation and outgrowth of additional replication-competent viruses was observed. This study 
revealed that one round of T cell activation does not induce all of the replication-competent 
proviruses in the LR. Thus, the size of the LR is larger than previously estimated. This work 
highlights the need to understand the extent to which these intact, noninduced proviruses pose a 
risk of viral rebound in patients who stop ART107,127. 
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Recent work has shown that expanded clones of infected cells are present in some 
patients on ART18,19,21. These studies suggested that integration of HIV-1 into growth-promoting 
and cancer-associated genes might drive clonal expansion of infected cells. Although the majority 
of clonally expanded cells are likely to contain defective proviruses, the possibility that cells 
carrying replication-competent proviruses can undergo extensive proliferation could further 
complicate eradication efforts. In a recent study of a patient with HIV-1 infection and squamous 
cell carcinoma, infectious virus has been recovered from a clone of CD4+ T cells that may have 
proliferated in response to the cancer20. 
In this study, we have addressed the issue of the true size of LR by isolating and 
characterizing inducible, replication-competent viruses that are missed by the standard VOA. We 
developed the multiple stimulation VOA (MS-VOA) that subjects resting memory CD4+ T cells 
from patients on suppressive ART to four rounds of maximum T cell activation. In addition, we 
performed an extensive phylogenetic analysis of all replication-competent viruses that grow out 
in this assay. Because this MS-VOA allows the isolation of large numbers of viral clones from 
each patient, we were able to demonstrate in most patients the presence of independently derived 
viral clones with identical sequences in the highly variable env gene. These results are consistent 
with the presence of expanded cellular clones carrying inducible, replication-competent viruses in 
patients. Taken together, our work supports a mechanism of stochastic reactivation of intact 
proviruses, including clonally expanded proviruses, and provides a new approach for estimating 




Materials and Methods 
Study subjects 
Peripheral blood was obtained from healthy volunteers and infected donors who had 
suppression of viremia to <20 copies HIV-1 RNA/ml for >6 months on ART. This study was 
approved by the Johns Hopkins Institutional Review Board. Written informed consent was 
obtained from all participants. 
Multiple Stimulation Viral Outgrowth Assay (MS-VOA) 
The MS-VOA was performed as described previously22, except that 200,000 patient cells 
were plated in 12-well transwell plates (Corning). A pure population of resting memory CD4+ T 
cells was isolated using a negative selection magnetic bead depletion (Miltenyi Biotec). PHA was 
added at a final concentration of .5 ug/mL and half the media from each transwell was removed 
2x the following day after PHA addition and replaced with fresh media. MOLT-4 cells were 
added to the bottom chamber of the transwell on day 146. Half the volume in the transwell was 
split into a new transwell before receiving an additional round of PHA and was done in a similar 
manner for all four rounds of PHA. The supernatant from each transwell was examined for p24 
capsid by ELISA (PerkinElmer) after 21 days. 
CFSE staining  
Staining was performed as described previously128,129. A 5mM CFSE stock was made by 
adding 18 uL of DMSO into an aliquot of CFSE. A working stock of 10uM CFSE was made by 
adding 2 uL of the stock into 1000 uL of PBS. The final concentration added to cells was 5 uM 
CFSE per 1 million cells. The dilution of CFSE was analyzed by flow cytometry using a 488 nm 
laser on a BD FACSCANTO II cytometer (BD Biosciences) with an emission of 492⁄517 nM. 
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The results were read using the BD FACSDiva™ software (BD Biosciences) and analyzed using 
FlowJo software.  
Activation and exhaustion marker staining  
  A week after each round of PHA activation, cells were stained with anti-CD4 (FITC), 
anti-CD25 (APC), anti-CD69 (APC), and anti-HLA-DR (APC) antibodies (BioLegend, San 
Diego, CA) and incubated at 4 C for 15-30 minutes. The stained cells were read by a 488 nM 
laser on a BD FACSCANTO II cytometer (BD Biosciences). Similarly to activation marker 
staining, cells were stained a week after each round of PHA activation with the exhaustion 
markers anti-PD1 (FITC), anti-CTLA-4 (PE), and anti-TIM-3 (P3/Cy7) antibodies (BioLegend, 
San Diego, CA) and were incubated at 4 C for 15-30 minutes. The results were read using the BD 
FACSDiva™ software (BD Biosciences) and analyzed using FlowJo software. 
Cell viability analysis 
The Zombie Red™ Fixable Viability Kit (BioLegend, San Diego, CA) was added to cells 
a week after each round of PHA activation. Cells were washed in PBS and 1 uL of the Zombie 
Red™ dye was added to 1 million cells. The stained cells were incubated at room temperature for 
15-30 minutes and then washed with PBS before being read by a 561 nM laser on a BD 
FACSCANTO II cytometer (BD Biosciences) with an emission of 624 nM. The results were read 
using the BD FACSDiva™ software (BD Biosciences) and analyzed using FlowJo software. 
RNA isolation and cDNA synthesis 
Viral RNA was isolated by adding 200 uL of the supernatant from each transwell in the 
MS-VOA and collected using a a ZR-96 Viral RNA Kit™ (Zymo Research Corporation, 
Irvine, CA). 4 uL of RNA from p24-positive wells were DNase-treated (Life 
Technologies, Carlsbad, CA) and reverse transcribed using the qScript cDNA synthesis 
kit (Quanta Biosciences, Gaithersburg, MD).  
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Amplification of env and LTR from outgrown replication-competent viruses 
A nested PCR for the V3/V4 region of env was performed on the cDNA from p24-
positive wells. Approximately 600ng of cDNA was used for the outer PCR reaction. The outer 
PCR products were diluted 1:50 and 5 uL of this dilution put into an inner PCR reaction. For env 
amplification, outer primers ES7 (CTGTTAAATGGCAGTCTAGC) and ES8 
(CACTTCTCCAATTGTCCCTCA) and inner primers Nesty8 (CATACATTGCTTTTCCTACT) 
and DLoop (GTCTAGCAGAAGAAGAGG) were obtained from Integrated DNA Technologies 
(Coralville, IA). Thermocycler settings were as follows for both outer and inner Env PCR 
reactions: 94C 3 min, 94C 30 sec, 55C 30 sec, 68C (1 min), Repeat cycles 2-4 39X following by 
68C for 5 min. PCR products were run on a 1% agarose gel and extracted using the QIAquick Gel 
Extraction Kit (Qiagen, Hilden, Germany). Extracted DNA was then Sanger sequenced at 
Genewiz, Inc. (Frederick, MD). Everything was done the same for LTR, except that for LTR 
amplification, outer primers 5LTROut (CACACAAGGCTAYTTCCCTGA) and mod_VQA_R 
(TTTTTTGAGGCTTAAGCAGTGGGTTCCCTA) and inner primers 5LTRIn 
(ACTGTCTAGATGGATGGTGCTWCAAGYTAGT) and mod_VQA_R (same as used in outer) 
were obtained from Integrated DNA Technologies (Coralville, IA). Thermocycler settings were 
as follows for both outer and inner LTR PCR reactions: 94C 3 min, 94C 30 sec, 55C 30 sec, 68C 
(1 min), Repeat cycles 2-4 39X following by 68C for 5 min. 
Amplification of env from proviral DNA in resting memory CD4+ T cells 
The limiting dilution PCR was performed as previously described26, except the outer PCR 
primers are the exact same ES7/ES8 primers used on the outgrown replication-competent virus in 
this study. 2 uL of the outer PCR product was added to the inner PCR reaction, which also uses 
the same Nesty8/DLoop primers used on the outgrown replication-competent virus. 
Thermocycler settings were as follows for both outer and inner Env PCR reactions: 94C 3 min, 
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94C 30 sec, 55C 30 sec, 68C (1 min), Repeat cycles 2-4 39X following by 68C for 5 min. PCR 
products were run on a 1% agarose gel and extracted using the QIAquick Gel Extraction Kit 
(Qiagen, Hilden, Germany). Extracted DNA was then Sanger sequenced at Genewiz, Inc. 
(Frederick, MD).  
Phylogenetic tree generation and sequence alignments 
Forward and reverse sequences for each sample were aligned into one consensus contig 
per sample using default assembly parameters on CodonCode Aligner software (CodonCode 
Corporation). Each sample consensus sequence was aligned with reference sequences of 
catalogued viruses from the Los Alamos National Laboratory online HIV sequence database 
(http://hiv.lanl.gov) using default assembly parameters that were adjusted to accommodate all 
sample and reference sequences. For phylogenetic tree generation, sequences were trimmed to the 
same length. Gaps were replaced with degenerate bases for both env and LTR sequences and 
aligned using BioEdit software. Maximum likelihood trees were created using 20 reference 
sequences from clades B and C viral sequences along with sequences from four stimulations done 
in all twelve patients. Trees were generated with a maximum composite likelihood algorithm and 
default parameters using MEGA5 software (Molecular Evolutionary Genetics Analysis 
Program)130,131 and a bootstrap analysis was performed with 1000 bootstrap samples. 
Clonal Prediction Score (CPS) 







The viral outgrowth assay can be modified to include multiple rounds of maximal T cell 
activation (MS-VOA) 
Reservoir quantitation by the VOA is based on the assumption that a single round of 
maximal T cell activation is sufficient to induce all of the replication-competent proviruses 
present in a given cell sample. Although the conditions used in the VOA activate 100% of patient 
resting CD4+ T cells, a recent study described the presence of large numbers of intact proviruses 
that are not induced in this assay, but are capable of robust in vitro replication when reconstructed 
by gene synthesis. Some of these intact, noninduced proviruses can be induced following a 
second round of T cell activation26. Based on these results, we modified the VOA to allow for 
four sequential rounds of T cell activation with PHA. In this multiple stimulation VOA (MS-
VOA), resting CD4+ T cells from patients on ART are seeded in 12-well transwell plates at 
200,000 cells per well, which represents a limiting dilution for viral outgrowth for most patients. 
The cells are activated with PHA and irradiated allogeneic PBMCs (Figure 3.1). Transwell plates 
are used to separate patient cells from the MOLT4–CCR5 cells, which are added to expand virus 
released from patient cells. Previous studies have shown that viral outgrowth is not affected by 
separating the cell populations by a semi-permeable membrane26. One week following the first 
round of activation, half of the volume in both the top and bottom chambers of each well of the 
initial set of transwell plates (designated Group A) is transferred into new transwell plates 
(labeled Group B) that receive a second round of PHA activation. The original wells are cultured 
without additional activation for a total of 21 days to allow for viral outgrowth. PHA induces T 
cells to undergo several rounds of division, and thus daughter cells in a given clonal population 
should be present in both the original and newly split wells26. A week following the second round 
of PHA activation, the Group B wells are split further to produce Group C wells which receive a 
third round of PHA activation, and the same is done a week later to generate Group D wells 
35	  
	  
which receive the fourth, and final, round of T cell activation. The readout for viral outgrowth 
from each round of activation is the same: a p24 ELISA performed three weeks following each 
respective round of PHA activation.  
Multiple rounds of maximal T cell activation induce outgrowth of additional replication-
competent viruses  
The MS-VOA was performed on purified resting CD4+ T cells from 12 patients on long 
term suppressive ART who had viral loads of below 20 copies per mL at the time of sampling. 
An equal number of male and female patients were recruited for this study.  Patient characteristics 
are given in Supplemental Table 3.1. Strikingly, in 12 of 12 patients we demonstrated additional 
outgrowth of replication-competent viruses with additional rounds of maximal T cell activation 
(Figure 3.2). In 11 of 12 patients, two rounds of maximal T cell activation were insufficient to 
induce all of the proviruses that were ultimately induced with the third and fourth rounds of T cell 
activation (Figure 3.2A). As is discussed below, the PHA stimulation protocol was chosen to 
ensure activation of 100% of the patient CD4+ T cells present. Thus, these results indicate that 
replication-competent proviruses can remain latent despite multiple rounds of maximal T cell 
activation and then subsequently reactivate. On average across 12 patients, one round of PHA 
resulted in reactivation of 19.31% of wells initially seeded with 200,000 resting CD4+ T cells, 
while the cumulative effects of four rounds of PHA stimulation resulted in viral outgrowth in 
cultures derived from of 30.81% of the initially seeded wells (Figure 3.2B). These results were 
used to calculate the frequency of latently infected cells detected after one round of PHA 
stimulation and after a total of four rounds of PHA stimulation (Figure 3.2C). The initial IUPM 
measured after one round of PHA represents the value that would be determined in the standard 
VOA132 while the total IUPM represents the best estimate of the total frequency of latently 
infected cells. On average in 12 patients, the total IUPM was two-fold larger than the initial 
IUPM value. These results show that while the standard VOA gives a minimal estimate of the 
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size of the LR, the MS-VOA gives a larger estimate that is close to the true frequency of latently 
infected cells. 
Analysis of cell division, activation marker expression, and exhaustion marker expression 
by cells in the MS-VOA  
The results presented above suggest that each round of stimulation with PHA induces 
additional latent proviruses to produce replication-competent virus. We next examined the effects 
of this repetitive stimulation on the patient CD4+ T cell populations harboring these proviruses 
(Figure 3.3). To determine whether the patient CD4+ T cells undergo normal cell division after 
each round of mitogen stimulation, we stained the cells with a fluorescent dye, 
carboxyfluorescein succinimidyl ester (CFSE), which is diluted with every round of cell 
division128,129.  We have previously used CFSE to show that 99.8% of patient CD4+ T cells have 
undergone division one week after the addition of PHA26. In this study, we found that a week 
following the first addition of PHA, >99% of the cells had undergone division (Figure 3.3A). 
The number of cells increased an average of 8-fold during this period (Supplementary Figure 
3.1A). After the first round of PHA stimulation, cells continued to proliferate, perhaps due to the 
presence of IL-2 in the media, and CFSE dilution was observed both in wells that received 
additional PHA stimulation and in wells that did not. In later rounds of stimulation, this 
proliferation was balanced by cell death as the total number of viable patient CD4+ T cells in the 
cultures showed smaller increases after the 2nd, 3rd, and 4th rounds of PHA stimulation (3.5-, 2.5-, 
and 2-fold respectively; Supplemental Figure 3.1). 
Although cells continued to proliferate throughout the course of the experiment, each 
additional round of PHA stimulation caused activation of the patient CD4+ T cells as evidenced 
by increased cell surface expression of CD25, CD69, and HLA-DR, which are expressed on 
activated T cells26. There was minimal expression of these markers on purified resting CD4+ T 
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cells prior to the PHA stimulation (Figure 3.3B). One week following the first stimulation, 
virtually all of the cells were positive for one or more markers. The activated cell populations 
showed a loss of activation markers if not given additional PHA stimulation (Figure 3.3B). Each 
additional round of stimulation caused an increase in activation marker expression relative to 
cells that did not receive that round of stimulation (Figure 3.3B). Thus, additional mitogen 
stimulation alters host gene expression, consistent with the induction of additional latent 
proviruses demonstrated above. The above result seen with CFSE and activation marker staining 
was seen in additional patients examined (Supplemental Figure 3.2). 
We also explored whether repetitive PHA stimulation caused T cell exhaustion133,134, 
possibly accounting for the lower number of latent proviruses induced by later rounds of 
stimulation. To determine if the cells in the MS-VOA developed an exhaustion phenotype, we 
stained patient cells with antibodies to PD-1, TIM-3, and CTLA-4, which are expressed on the 
surface of exhausted CD4+ T cells135-139. We found no increased expression of PD-1 and CTLA-
4, but a small increase in expression of TIM-3 after three rounds of PHA stimulation, with a 
further increase in TIM-3 after the fourth round of activation (Figure 3.3C). This result is 
consistent with previous work showing an increase in TIM-3 expression on CD4+ T cells that 
have undergone a strong stimulation via the T cell receptor140. In addition, cell viability decreased 
with each subsequent round of PHA stimulation (Supplemental Figure 3.1). Thus, the additional 
viral outgrowth obtained with multiple stimulations, while greater than that seen in the standard 
VOA, may represent only a minimum estimate of the true reservoir size due to the effects of 
increasing cell exhaustion and decreasing viability in long term in vitro culture. 
The MS-VOA supports stochastic activation of latent proviruses 
The MS-VOA allowed us to obtain large numbers of clones of replication-competent 
virus from most patients. To analyze the relationship between viral clones that grew out after 
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different numbers of PHA stimulations, we first asked whether there were any genetic differences 
in the U3 region of the LTR region (Figure 3.4). This promoter region is critical for transcription 
of the provirus since it contains binding sites for essential transcription factors141,142, such as NF-
kB117 and SP1143. We hypothesized that mutations in the transcription factor binding sites might 
explain why some viruses require additional rounds of T cell activation for outgrowth. Therefore, 
we sequenced the U3 region of the LTR from each of the viral isolates from five patients. In 
phylogenetic analysis, sequences from each patient clustered separately from each other and from 
reference Clade B sequences and more distantly related Clade C viruses (Figure 3.4A). We found 
no significant changes in the transcription factor binding sites amongst the viruses that had grown 
out with different number of stimulations in each patient (Figure 3.4B). These results suggest that 
the U3 region of the LTR does not account for why some viruses are only induced after additional 
rounds of T cell activation. 
We next hypothesized that viruses arising earlier in the course of infection may have 
resided in a latent state for a longer period of time, making them harder to reactivate due to 
progressively deeper levels of epigenetic silencing144 To address this issue, we sequenced a 500 
bp region of the env gene (V3/V4) from each of the outgrowth viruses from all 12 patients 
(Figure 3.5A). Sequences from each patient clustered separately from each other and from 
reference Clade B sequences and more distantly related Clade C viruses. Within individual 
patients, there was substantial diversity within the env sequences, consistent with the fact that 
most patients initiated ART during chronic infection (Figure 3.5F and Supplemental Table 
3.1). Sequence variants arising earlier in the course of infection are expected to show a lower 
degree of evolutionary divergence from the ancestral sequence145. We examined the relationship 
between the distance from the most recent common ancestor (MRCA) and the number of 
stimulations required to induce viral outgrowth (Figure 3.5G). We found that there was no 
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relationship between divergence and the number of stimulations, further supporting the 
mechanism of stochastic reactivation of HIV-1 from the LR. 
Expanded clones of CD4+ T cells harboring replication-competent virus are readily 
detected with the MS-VOA in most patients on suppressive ART 
  Because the MS-VOA allowed us to obtain large numbers of independent isolates of 
replication-competent virus from each patient, we were able to examine the issue of whether 
clonal expansion of infected cells contributed to the LR. Studies of HIV-1 integration sites have 
provided evidence for clonal expansion18,19, but the majority of expanded cellular clones may 
contain defective proviruses20,21,26. Surprisingly, we found that despite the high level of sequence 
variability in the V3/V4 region of env, 9 of 12 patients had one or more sets of replication-
competent viral isolates with identical sequences in this region (Figure 3.5A). For representative 
patients with multiple identical isolates, we also carried on limiting dilution amplification and 
sequencing of the V3/V4 regions of proviruses present in resting CD4+ T cells isolated directly 
from the same patients without culture (Figure 3.5B-D). For patient 2, we found two sets of 
identical sequences among the replication-competent isolates from the MS-VOA (designated here 
Set 2.1 and Set 2.2) (Figure 3.5E). Aside from patient 2, we found sets of identical viral 
sequences from 8/12 other patients (Figure 3.5F). Together, these results suggest that expanded 
cellular clones with identical viral sequences are present in many patients and that some of these 
clones harbor replication competent virus.  
A caveat to this conclusion is that viruses with identical env sequences may differ 
elsewhere in the genome and thus may not originate from an expanded cellular clone. For patients 
1 through 5, we showed that isolates with identical env sequences also had identical LTR 
sequences (Figure 3.4A), further supporting the conclusion that they originated from an 
expanded cellular clone. In addition, for these isolates we determined the Clonal Prediction Score 
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(CPS), an estimate of how much false-positive clonality should be expected in a phylogenetic tree 
generated using a given primer set (Figure 3.6A). It is based on an analysis of available sets of 
full genome sequences from individual patients (Laskey S.B. et al. Manuscript submitted). In 
Figure 3.6A-C, the CPS values for the primer sets used to generate the sequences are plotted as 
black lines representing the slope of a plot of the number unique sequences in a phylogenetic tree 
vs. the number of total sequences in the tree. The dashed red lines indicate one standard deviation 
above or below the CPS. The phylogenetic tree for each patient is plotted as a point. Points falling 
far below the black line in the green-shaded region (e.g. the dots representing Patient 2) are more 
likely to represent true clonal expansion.  These results show that the identical viral isolates 
obtained from approximately half of the patients that were sequenced for both env and LTR are 
likely to represent true clones. The proportion of clonal sequences did not increase with 
increasing time on ART (Figure 3.6B) or with the final IUPM as measured by the MS-VOA 
(Figure 3.6C). Interestingly, identical isolates, including those with a high probability of 
representing true clones, were often obtained after different numbers of stimulations (Figure 
3.5A-F), consistent with the stochastic activation of otherwise identical proviruses in the LR. 
Taken together, our results show that in patients on suppressive ART, there are populations of 
latently infected cells, including clonally expanded cells, that release replication-competent virus 
in a stochastic manner after maximal T cell activation and that multiple rounds of maximal 









Multiple Stimulation Viral Outgrowth Assay (MS-VOA) enables up to four rounds of 
maximal T cell activation 
The latent reservoir (LR) remains the major barrier to eradication of HIV-1146-148. Since 
the LR is stable and would require suppressive ART for the lifetime of a patient in order to 
eliminate all latently infected cells6,7,149, there is not only an urgent need to find therapeutic 
strategies to eliminate the LR, but a need for assays that can accurately measure the size of the 
LR148. While there are many PCR- and culture-based assays that are used to measure the size of 
the LR, none correlate with one another16,17 and poses a problem when accurately interpreting 
results of eradication clinical trials. A true cure cannot be confidently assessed if a decrease in the 
size of the LR has not been accurately observed. In our study, we developed the MS-VOA, which 
is a modified viral outgrowth assay that includes up to four consecutive rounds of maximal T cell 
activation given at weekly intervals. We performed the MS-VOA on 6 male and 6 female patients 
that initiated ART during the chronic phase of infection. We observed additional outgrowth of 
replication-competent virus past a single round of T cell activation in all 12 patients and had 
10/12 patients that required more than two rounds of activation. In addition, the IUPM after four 
rounds of T cell activation was shown to be twice as large versus just one round of T cell 
activation in the standard VOA, giving a better estimate of the frequency of latently infected cells 
within patients on suppressive ART. These results are consistent with previous studies showing 
that the size of the LR is larger than originally estimated26 and provides a more accurate IUPM 
measurement.  
The MS-VOA is comprised of four consecutive viral outgrowth assays with cells 
showing continuous division and expression of activation markers with the administration of each 
round of T activation. In addition, we found that expression of an exhaustion marker, TIM-3, 
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increases after the third round of T cell activation and increases even more in the fourth round. 
This increase was associated with some degree of resistance to reactivation and may provide an 
explanation for the reduced viral outgrowth observed with later rounds of PHA stimulation. Even 
with limitations inherently present with the VOA22,132,150, the MS-VOA provides both a more 
accurate IUPM measurement and strongly supports a stochastic mechanism of HIV-1 reactivation 
from the LR. 
Replication-competent viral clones are released from different rounds of maximal T cell 
activation  
We constructed a phylogenetic tree by sequencing both the U3 region of LR as well as 
the V3/V4 region of the env gene in all outgrown replication-competent virus in the MS-VOA. 
We wanted to see if there was a correlation between regions of the viral genome and the round of 
T cell activation the virus grew out in, but found no correlation. To our surprise, we found distinct 
sets of matching viral sequences that share sequence similarity of the V3/V4 region of env in 
10/12 patients. In one particular patient, all the replication-competent outgrown virus divided into 
two distinct sets of clones that were 100% similar by nucleotide composition. This observation 
supports previous work on clonal expansion of HIV-infected cells18-21. With our extensive 
phylogenetic analysis showing a set of replication-competent viral clones present in 10/12 
patients, we wanted to determine how likely these identical env and LTR sequences represent true 
viral clones. We performed a Clonal Prediction Score (CPS) on these sequences and confirmed 
that a population of clonally expanded cells present in some patients on suppressive ART. Taken 
together, our results not only strongly support the stochastic reactivation of virus, but shows that 





Clonal expansion of HIV-infected resting CD4+ T cells complicates eradication efforts  
Further studies will need to examine the role of clonal expansion as an even larger barrier 
to the cure of HIV-1151. Recent studies have shown HIV-1 integrates into growth-promoting 
genes in the human genome and suggests that this could contribute to clonal expansion of 
infected cells18,19,21. Although one of the studies suggests the presence of defective HIV-1 in 
clonally expanded cells, a recent longitudinal study has shown matching plasma viral sequences 
to integrated DNA seen in resting T cells, suggesting the contribution of replication-competent 
virus released from clonally expanded cells to residual viremia152. Furthermore, Simonetti and 
colleagues showed the presence of replication-competent virus from a population of clonally 
expanded tumor infiltrating T cells in a patient that had squamous cell carcinoma20. Our work not 
only supports the presence of clonally expanded cells containing replication-competent virus, but 
also further shows a stochastic mechanism of reactivation from these clonally expanded cells. 
Further studies will need to be done in order to identify the integration sites that the outgrown 
viruses in the MS-VOA. The integration site the replication-competent viruses come from would 
provide key insight into why some replication-competent viruses come out in one round of 
maximal T cell activation versus multiple rounds. If viruses that replicate from different rounds of 
activation arise from the same integration site in clonally expanded cells, this would even further 
strongly support stochastic reactivation of viruses from the LR as observed in previous studies26 
and would strongly urge the field to focus efforts on employing different strategies to eliminate 
the LR. In addition, it is important to elucidate whether the latency reversing agents currently 
studied in the field may contribute to the clonal expansion of infected cells, which would increase 
the size of the LR and further complicate eradication efforts. Thus, the mechanism of stochastic 
reactivation of replication-competent virus from clonally expanded cells in the LR needs to be 




Figure 3.1.  Multiple Stimulation Viral Outgrowth Assay (MS-VOA). 
Purified resting CD4+ T cells from patients on suppressive ART are plated at 2 x 105  cells/well 
in the top chambers of 12-well transwell plates in media supplemented with growth factors and 
IL-2. PHA and irradiated allogeneic healthy donor PBMCs are added to each well. PHA is 
removed after 24 hours and 106 MOLT4-CCR5 cells are added to the bottom chamber of each 
transwell. The initial set of plates (Group A) are cultured for 8 days following the first round of 
activation, and then half of the volume from both the top and bottom chambers of each transwell 
is transferred to a fresh set of transwell plates (Group B) for a second round of PHA activation. 
The Group A plates are cultured without further activation for a total of 21 days. The group B 
plates are cultured for 8 days following the second round of PHA activation and then split as 
above to generate Group C plates, which receive a third round of activation. Similarly, these 
plates are split 8 days after activation to generate the Group D plates, which receive a fourth 
round of activation. A p24 ELISA for the capsid protein of the virion is performed 3 weeks after 
each respective round of PHA activation to quantify viral outgrowth. 
 
















Figure 3.2. Further rounds of T cell activation in the VOA induce additional proviruses to 
produce replication-competent virus.  
 (A) The number of p24-positive wells resulting from of each round of T cell activation.  For each 
patient, a total of 64-72 wells were initially seeded with 2x105 cells/well. Cells from each well 
received 4 rounds of T cell activation (except for cells from Patient 1 which only received three 
total rounds of PHA activation). (B) The percent of p24-positive wells detected after the first 
round of T cell activation or after subsequent rounds. The denominator is the total number of 
wells initially seeded with 200,000 resting CD4+ T cells. (C) The initial and final IUPM values 
calculated from the number of p24-positive wells after one round of activation and after a total of 
4 rounds of PHA stimulation.  
  







































































Figure 3.3. Cells divide and express activation markers after each round of activation and 
express TIM-3 after the third round of activation. 
(A) Effect of each round of PHA stimulation on proliferation of patient CD4+ T cells.  
Immediately prior to PHA stimulation, patient cells were stained with CFSE. An aliquot of cells 
were analyzed 1 day after stimulation (orange histograms). Cells were analyzed by flow 
cytometry one day after addition of PHA as an internal gating control for the decrease in CFSE 
(orange histograms). Another aliquot of cells was analyzed 7 days activation to determine the 
percentage of cells that had undergone division (red histograms). Cells that did not receive the 
additional round of PHA stimulation served as controls (blue histograms). Results are shown for 
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Patient 8 and are representative of 2 other patients analyzed. (B) Expression of activation markers 
following each round of PHA stimulation. Cells were stained with antibodies to CD4 (x-axis), 
and the activation markers CD25, CD69, and HLA-DR (y-axis) one week after each round of 
PHA stimulation (red dot plots). Cells that did not receive the relevant round of PHA stimulation 
were analyzed in parallel (blue dot plots). Results are shown for patient 10 and are representative 
of 2 other patients analyzed. (C) Expression of exhaustion markers after each round of PHA 
stimulation. Cells were stained with antibodies to the exhaustion markers PD-1, CTLA-4, and 
TIM-3 one week after each round of T cell activation. Results are shown for patient 10 and are 















Figure 3.4. The U3 region of LTR does not account for viruses growing out in different 
number of stimulations. 
(A) The U3 region of LTR containing the transcription factor binding sites was sequenced for all 
outgrown replication-competent viruses in patients 1 through 5 in the MS-VOA. The sequences 
were aligned in CodonCode software and a neighbor-joining phylogenetic tree of all outgrown 
sequences in all 12 patients was generated using the MEGA software. The orange open boxes 
represent consensus sequences from a Clade C virus and the purple open boxes represent 
consensus sequences from a Clade B virus; all consensus sequences were retrieved from the Los 
Alamos National Laboratory HIV website (http://hiv.lanl.gov). An asterisk (*)  indicates 
bootstrap support ≥75%. (B) A representative set of viral sequences from different stimulations in 
each patient shown in (A) was aligned using BioEdit software. The different letters indicate 
which stimulation the virus grew out from: A is Stim 1, B is Stim 2, C is Stim 3, and D is Stim 4. 






Figure 3.5. Patients on suppressive ART contain a distinct set of expanded replication-
competent viral clones. 
(A) The V3/V4 region of env was sequenced for al outgrown replication-competent viruses in al 
12 patients in the MS-VOA. The sequences were aligned in CodonCode software and a neighbor-
joining phylogenetic tree of al outgrown sequences in al 12 patients was generated using the 
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                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HXB2               ATGCTAAAACCATAATAGTACAGCTGAACACATCTGTAGAAATTAATTGTACAAGACCCAACAACAATACAAGAAAAAGAATCCGTATCCAGAGAGGACC 
P2_A12             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A13             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A20             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A23             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A33             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A40             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A45             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A48             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A55             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_B22             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_B30             ...................G..T.....TGA....A...T...G...........G.....T...........-...G.-----....A..T.T...... 
P2_A16             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
P2_A32             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
P2_A37             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
P2_A42             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
P2_A54             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
P2_B57             ...................G..T.....TGA....A...TG..G...........G.....T...........-...G.-----....A..T.T...... 
                           110       120       130       140       150       160       170       180       190       200         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HXB2               AGGGAGAGCATTTGTTACAATAG--GAAA-AATAGGAAATATGAGACAAGCACATTGTAACATTAGTAGAGCAAAATGGAATAACACTTTAAAACAGATA 
P2_A12             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A13             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A20             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A23             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A33             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A40             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A45             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A48             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A55             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_B22             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_B30             C..C.........TA.G...C..GA....T............A.....G............C.....G..A..C....................A..... 
P2_A16             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
P2_A32             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
P2_A37             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
P2_A42             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
P2_A54             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
P2_B57             ...C.........TA.G...C..GA....T.......G....A.....G............C.....G..A..C....................A..... 
                           210       220       230       240       250       260       270       280       290       300         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HXB2               GCTAGCAAATTAAGAGAACAATTTGGAAATAATAAAACAATAATCTTTAAGCAATCCTCAGGAGGGGACCCAGAAATTGTAACGCACAGTTTTAATTGTG 
P2_A12             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A13             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A20             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A23             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A33             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A40             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A45             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A48             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A55             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_B22             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_B30             .T..TA...C.............------.............G.A......A.C........................AC..T..T.............. 
P2_A16             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
P2_A32             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
P2_A37             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
P2_A42             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
P2_A54             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
P2_B57             ....CA.G.....A.........------.............G.A......A.C........................AC..T..T.............. 
                           310       320       330       340       350       360       370       380       390       400         
                   ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
HXB2               GAGGGGAATTTTTCTACTGTAATTCAACACAACTGTTTAATAGTACTT---------GGTTTAATAG---------------------TACTTGGAGTAC 
P2_A12             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A13             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A20             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A23             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A33             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A40             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A45             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A48             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A55             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_B22             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_B30             ....A........................................A..CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A16             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A32             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A37             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A42             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
P2_A54             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
P2_B57             .T..A........................................AC.CAACACAACT.........---------------------..AG.TA.A.GA 
                           410       420       430       440       450       460     
                   ....|....|....|....|....|....|....|....|....|....|....|....|....
HXB2               TGAAGGGTCAAATAACACTGAAGGAAGTGACACAATCACCCTCCCATG---CAGAATAAAACAA 
P2_A12             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A13             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A20             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A23             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A33             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A40             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A45             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A48             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A55             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_B22             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_B30             CAC.A--...C.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A16             CAC.A--...T.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A32             CAC.A--...T.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A37             CAC.A--...T.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A42             CAC.A--...T.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 
P2_A54             CAC.A--...T.CTC.CA..C..A.TAAA...A.T.ATAAAC---...TGG....CAGT.GG.. 






































































and the purple open boxes represent consensus sequences from a Clade B virus; all consensus 
sequences were retrieved from the Los Alamos National Laboratory HIV website 
(http://hiv.lanl.gov). Circles represent Stim 1 viruses, triangles represent Stim 2, squares represent 
Stim 3, and diamonds represent Stim 4 viruses. Arrows indicate a set of >2 outgrown virus that 
contain the same V3/V4 region of env. An asterisk (*) indicates bootstrap support ≥75%. (B) The 
V3/V4 region was sequenced on proviral DNA from resting memory CD4+ T cells isolated from 
Patient 11 at the time the MS-VOA was done. A limiting dilution method was done to ensure that 
the proviral sequences are clonal as described in 26. The proviral sequences are depicted as open 
circles, while the MS-VOA outgrown replication-competent viruses are represented in shaded 
symbols. An asterisk (*)  indicates bootstrap support ≥75%. The same limiting dilution proviral 
sequencing for V3/V4 was done for  (C) Patient 2 and (D) Patient 5. (E) V3/V4 sequences from 
the two sets of distinct replication-competent clones from Patient 2 in (C) were aligned using 
BioEdit software. The different letters indicate which stimulation the virus grew out from: A is 
Stim 1 and B is Stim 2. (F) Phylogenetic trees of the V3/V4 region of env from left to right: 
Patient 1, Patient 3, Patient 6, Patient 9, Patient 10, and Patient 12. Arrows indicate a set of >2 
outgrown virus that contain the same V3/V4 region of env. An asterisk (*) indicates bootstrap 
support ≥75%. (G) The average branch length from the most recent common ancestor (MRCA) in 
the phylogenetic trees for each patient shown in (A) was plotted against the stimulation that 









Figure 3.6. Quantitative analysis of clonaly expanded replication-competent viral clones. 
(A) A quantitative analysis of clonal expansion was performed using the Clonal Prediction Score 
(Laskey S.B. et al. Manuscript submited). The alignments used to generate the env phylogenetic 
trees in Figure 3.5A, LTR phylogenetic tree in Figure 3.4A, and a combination of the two are 
ploted as dots, indicating the relationship between the total number of sequences and the number 
of unique sequences in each alignment. The black line shows the expected false-positive clonality 
rate for the amplicons used to generate these alignments. Points that fal on or near the black line 
are likely to represent samples without clonally expanded genomes. Points that fal far below the 
black line (green shaded area) indicate patients with a high likelihood of true clonality. (B) The 
time the patient was on ART until the time of blood draw was ploted against the percent of 
replication-competent clones present after the MS-VOA; the coefficient of determination was 
calculated (R2 = 0.07106). (C) The change from initial to final IUPM as calculated by the MS-
VOA was ploted against the percent of replication-competent clones present after the MS-VOA; 
the coefficient of determination was calculated (R2 = 0.01874). 
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Supplemental Figure 3.1. Analysis of CD4+ T cell proliferation and cell death in MS-VOA 
cultures. 
(A) Total CD4+ T cell numbers in MS-VOA wells. The total number of cells in individual MS-
VOA transwells were counted one week after each PHA stimulation. By this point, the lethally 
irradiated allogeneic PBMC used in the PHA stimulation had all died.  Therefore, cell counts 
reflect the number of patient CD4+ T cells remaining in the culture. The input value for each well 
was 2x105 cells. Total cell numbers were corrected for the effect of splitting the wells during each 
PHA stimulation. (B) Cell  viability assessed using  an amine-reactive fluorescent dye to which 
viable cells are impermeable.  


































Supplemental Figure 3.2. Additional patients show cells divide and express activation 
markers after each round of activation. 
(A) Expression of activation markers following each round of PHA stimulation. Cells were 
stained with antibodies to CD4 (x-axis), and the activation markers CD25, CD69, and HLA-DR 
(y-axis) one week after each round of PHA stimulation (red dot plots). Cells that did not receive 
the relevant round of PHA stimulation were analyzed in parallel (blue dot plots). Results are 
shown for patient 11. (B) Results shown for patient 10. Effect of each round of PHA stimulation 
on proliferation of patient CD4+ T cells. Immediately prior to PHA stimulation, patient cells were 
stained with CFSE. One week later, dilution of CFSE was analyzed by flow cytometry and used 
to determine the percentage of cells that had undergone division (red histograms). Cells were 
sampled a day after addition of PHA as an internal gating control for the decrease in CFSE 
(orange histograms). Cells that did not receive an additional round of PHA stimulation served as 











































































































































































































































































Table 1. Patient Characteristics!
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
1 Time of initial diagnosis 
2 Time at sampling 
3 Time at sampling 
4 ABC/3TC = abacavir sulfate/lamivudine; DRV/r = darunavir/ritonavir; ETR = etravirine; RAL =  
raltegravir; ATV/r = atazanavir/ritonavir; FTC/TDF = tenofovir/emtricitabine; MVC = maraviroc; NVP = 









(c/ml)3 ART at time of draw4 
1 M 205 205 682 <20    ABC/3TC, DRV/r 
2 F 190 185 1,115 <20 DRV/r, ETR, RAL 
3 F 116 36 624 <20 ATV/r, FTC/TDF 
4 F 133 116 450 <20 DRV/r, MCV, RAL 
5 F 184 183 800 <20 ABC/3TC, NVP 
6 M 250 208 1,478 <20 EFV/FTC/TDF 
7 M 192 167 706 <20 FTC/RPV/TDF, DTG 
8 M 350 56 865 <20 EFV/FTC/TDF 
9 M 278 181 1,156 <20 ABC, ETR, 3TC, RAL 
10 F 208 100 771 <20 FTC, LPV/r, RAL 
11 M 101 49 962 <20 TDF/FTC, DTG 



















The importance of accurately measuring the HIV-1 latent reservoir  
 Latently infected resting CD4+ T cells are not targeted by the immune system or ART, 
making the latent reservoir (LR) the major barrier to cure. In addition, the LR is extremely stable 
and would take the entire lifetime of a patient to eliminate6,7. Current eradication clinical trials 
aim to reverse latency by using pharmacological agents that employ the ‘shock and kill’ strategy, 
through which latency is reversed such that now the infected cell can then recognized and ‘killed’ 
by the immune system15. Even if the field finds promising pharmacological agents and other 
therapeutic interventions to reverse latency15,32,148, there needs to be an assay that can accurately 
detect a decrease in the LR in patients. To date, PCR- and culture-based assays are used to 
measure the LR17, but don’t correlate with one another16,153. PCR-based assays overestimate the 
size of the LR and fail to distinguish between replication-competent and defective proviruses. 
Culture-based assays that use a single round of maximum T cell activation do not activate all 
latently infected cells with replication-competent viruses17,26. For these reasons, it is critical to 
develop an assay that can accurately measure the size of the LR.  
The MS-VOA provides a more accurate measure of the size of the latent reservoir 
 Not all proviruses in the LR are induced by a single round of maximal T cell activation. 
Previous work has shown additional viral outgrowth after a second round of maximal T cell 
activation26. My graduate thesis work has aimed at taking these previous findings further to 
develop and modify the quantitative viral outgrowth assay (QVOA) to include multiple 
stimulations (MS-VOA), specifically four rounds of maximal T cell activation. The MS-VOA 
was performed on resting cells isolated from 12 patients on suppressive ART treated during the 
chronic phase of infection. Results from my work showed that two rounds of maximal T cell 
activation were insufficient to induce all replication-competent viruses in 11/12 patients. In 
addition, the frequency of latently infected cells, as measured by IUPM (infectious units per 
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million), was two-fold larger than the initial IUPM value calculated after the first round of 
activation. The development of the MS-VOA has been important in advancing the field and may 
assist in interpreting eradication clinical trials since it gives a larger estimate may be closer to the 
true frequency of latently infected cells in vivo. 
Clonal expansion of latently infected cells may add an additional barrier to curing HIV-1  
In addition to providing a more accurate measurement of the size of the LR, the MS-
VOA revealed the presence of large numbers of clones of replication-competent virus from most 
patients. Sequencing of the V3/V4 region of the env gene in all outgrown virus revealed that 9/12 
patients had one or more identical sets of replication-competent viral isolates from different 
rounds of activation. This result is significant in light of recent work that has shown the presence 
of clonally expanded resting CD4+ T cells18,19 and how the majority of these expanded cells 
contain defective proviruses21. However, a very recent study has shown the presence of 
replication-competent virus in clonally expanded cells in a single patient that had squamous cell 
carcinoma20. My work supports the presence of clonally expanded cells harboring latent HIV-1 
and also shows how these expanded cells can release replication-competent in a stochastic 
manner. This work is significant in advancing the field since it not only highlights the presence of 
clonally expanded latently infected cells, but provides evidence of these cells harboring 
replication-competent viruses that can be released in stochastic manner after maximal T cell 
activation. This suggests the possibility of the LR increasing in size due to the presence of these 
clonally expanded cells and, thus, would add an additional barrier to eradication of HIV-1.  
Future work will need to thoroughly determine the contribution of these clonally 
expanded cells to the size of the LR. In addition, it will be important to analyze where HIV-1 
integrates in clonally expanded cells. Knowing if certain integration sites are more likely to 
contain inducible proviruses would enable better strategies to specifically target the replication-
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competent viruses in these clonally expanded cells. For example, an elegant study has shown that 
specific integration sites in MKL2 and BACH2 lead to clonal expansion of infected cells18. 
However, it has not been shown if proviruses integrated into either MKL2 or BACH2 are 
replication-competent. Further studies will need to be done to identify the integration sites of the 
outgrowth viruses in the MS-VOA to determine whether this can account for stochastic activation 
of latently infected, clonally expanded CD4+ T cells.  
The development of the MS-VOA was initially developed to serve as a more accurate 
measure of the LR, but in addition has revealed populations of latently infected cells, including 
clonally expanded cells, that release replication-competent virus in a stochastic manner after 
multiple rounds of maximal T cell activation. This work strongly suggests that multiple rounds of 
maximal activation may be required to fully purge the LR. The work presented in this thesis 
highlights the need for the development of additional assays that accurately measure the size of 
the LR, but also readdresses current strategies to eliminate the LR, which should include targeting 
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